[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338374-105":59,"doc-detail-338374-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-utility-of-circulating-tumor-dna-for-detecting-lung-cancer-mutations-by-targeted-next-generation-sequencing-with-insufficient-tumor-samples","Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next-Generation Sequencing With Insufficient Tumor Samples","","Circulating tumor deoxyribonucleic acid (ctDNA) is increasingly used in clinical practice, but its performance for detecting lung cancer mutations when tumor tissue is inadequate remains to be clarified. This research evaluated targeted next-generation sequencing (NGS) of ctDNA against matched tissue DNA (tDNA) in 60 non–small cell lung cancer patients. Thirteen driving genes were assessed with overall concordance 75.47%, sensitivity 77.55%, and specificity 50%. EGFR mutations were most frequent, with plasma-only alterations observed for several genes, supporting ctDNA feasibility for molecular diagnosis when biopsies are insufficient.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-utility-of-circulating-tumor-dna-for-detecting-lung-cancer-mutations-by-targeted-next-generation-sequencing-with-insufficient-tumor-samples/338374/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-utility-of-circulating-tumor-dna-for-detecting-lung-cancer-mutations-by-targeted-next-generation-sequencing-with-insufficient-tumor-samples/338374.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main objective?","Question",{"text":112,"@type":113},"To evaluate the clinical utility of ctDNA for targeted next-generation sequencing in non–small cell lung cancer patients with insufficient tumor samples.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was ctDNA tested in the study?",{"text":117,"@type":113},"Targeted DNA sequencing was performed on tissue biopsies and matched plasma samples from 60 patients with NSCLC.",{"name":119,"@type":110,"acceptedAnswer":120},"What diagnostic performance did ctDNA show compared with tissue DNA?",{"text":121,"@type":113},"Overall concordance between ctDNA and tDNA was 75.47%, with 77.55% sensitivity and 50% specificity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338374,1790819973,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Journal of Clinical Laboratory Analysis  \nRESEARCH ARTICLE  OPEN ACCESS   \nClinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next-Generation Sequencing With Insufficient Tumor Samples  \nYi Sun1 | Xu Zhang2 | Xinhua Yang2 | Jiangjun Ma2   \n1Pediatric, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China | 2Department of Molecular Diagnostics, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative  \nInnovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong Province, China Correspondence: Jiangjun Ma ([majj@sysucc.org.cn](majj@sysucc.org.cn))  \nReceived: 14 February 2024 | Revised: 7 August 2024 | Accepted: 28 August 2024  \nFunding: This research was funded by the Guangdong Basic and Applied Basic Research Foundation (Grant number 2019A1515011330) .  \nKeywords: circulating | gene mutations | lung cancer | next-generation sequencing | tumor DNA  \nABSTRACT  \nBackground: Circulating tumor deoxyribonucleic acid (ctDNA) is increasingly applied in clinical practice. This study aimed to explore clinical utility of a minimal invasive and sensitive way of ctDNA for next-generation sequencing in non–small cell lung cancer (NSCLC) with inadequate tumor samples.  \nMethods: Targeted DNA sequencing was performed on tissue biopsies and matched plasma samples from 60 patients with NSCLC.  \nResults: A total of 13 driving genes were detected in 60 matched tissue DNA (tDNA) and ctDNA samples. Overall concordance rate was 75.47%, with 77.55% sensitivity and 50% specificity. Epidermal growth factor receptor (EGFR) mutations were the most common in both tDNA and ctDNA samples. Among other mutated genes were tumor protein p53 (TP53), erb-b2 receptor tyrosine kinase 2 (ERBB2), anaplastic lymphoma kinase (ALK), cyclin-dependent kinase inhibitor 2A (CDKN2A), ros proto-oncogene 1, and receptor tyrosine kinase (ROS1). Mutations in b-raf proto-oncogene, serine/threonine kinase (BRAF), cluster of differentiation 274 (CD274), neurotrophin receptor tyrosine kinase 1 (NTRK1), and rearranged during transfection (RET) occurred only in plasma. The majority of mutations in both samples were single-nucleotide variants. Deletions were found in EGFR, BRAF, and TP53 in ctDNA, whereas in tDNA, deletions were only found in EGFR. In ALK, single nucleic acid-site amplification occurred simultaneously in tissue and plasma, but insertions and copy number variations were detected only in plasma.  \nConclusions: Identifying ctDNA mutations by targeted sequencing in plasma is feasible, showing the clinical value of ctDNAtargeted sequencing in NSCLC patients when tumor tissue sampling is insufficient or even impossible.  \n1 | Introduction  \nLung cancer is one of the most dangerous malignancies, with morbidity and mortality increasing faster in the population than other cancers [1]. Approximately 80% of lung cancer patients are diagnosed with locally advanced or metastatic non–small cell  \nlung cancer (NSCLC) [2] . At present, diagnostic biopsy specimens is the main method of tumor genotyping. In addition, the treatment for NSCLC is evolving to individualized treatment based on molecular alteration [3–5] . Unfortunately, in the actual course of the disease, it is difficult or impossible for many patients with advanced cancer to have biopsies. Therefore, this  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2024 The Author(s). Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.  \nJ","cbCaim4u8kc9w47z","https://ap.wps.com/l/cbCaim4u8kc9w47z","pdf",1936402,15,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the study’s main objective?\",\"answer\":\"To evaluate the clinical utility of ctDNA for targeted next-generation sequencing in non–small cell lung cancer patients with insufficient tumor samples.\"},{\"question\":\"How was ctDNA tested in the study?\",\"answer\":\"Targeted DNA sequencing was performed on tissue biopsies and matched plasma samples from 60 patients with NSCLC.\"},{\"question\":\"What diagnostic performance did ctDNA show compared with tissue DNA?\",\"answer\":\"Overall concordance between ctDNA and tDNA was 75.47%, with 77.55% sensitivity and 50% specificity.\"}]","Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next-Generation Sequencing With Insufficient Tumor Samples | PDF",1790023314,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45c3f4508f30edfc71243371094fafa2.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/137d31986820d83da354eeb8c17d8b96.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3506b6fb70007dda76406c350f125f2f.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83c9078358e5e354a686fdc21e6e7dc7.webp",980,1287]